Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients With Malignant Solid Tumors

NCT05539157 is registered in ClinicalTrials.gov with Immorna Biotherapeutics, Inc. as lead sponsor.

NCT NCT05539157
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05539157 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients With Malignant Solid Tumors
Lead sponsor
Immorna Biotherapeutics, Inc.
Phase
Phase 1
Overall status
Unknown status
Start date
October 18, 2022
Completion date
May 31, 2024
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous tumor, malignant solid tumor